Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 145

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood (2024) 144 (Supplement 1): 446.

https://doi.org/10.1182/blood-2024-203938

Published: 2024

Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 734.

https://doi.org/10.1182/blood-2024-203459

Published: 2024

Journal Articles

Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia

Roberta Santos Azevedo, Hagop M. Kantarjian, Koichi Takahashi, Cedric Christophe Nasnas, Sanam Loghavi, Nitin Jain, Fadi G. Haddad, Jayastu Senapati, Ghayas C. Issa, Hussein A. Abbas, Tapan M. Kadia, Kelly S. Chien, Guillermo Montalban-Bravo, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 728.

https://doi.org/10.1182/blood-2024-207745

Published: 2024

Journal Articles

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Walid Macaron, Elias Jabbour, Nitin Jain, Fadi G. Haddad, Jayastu Senapati, Partow Kebriaei, Eitan Kugler, Kelly S. Chien, Ghayas C. Issa, Jairo Matthews, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 727.

https://doi.org/10.1182/blood-2024-203929

Published: 2024

Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood (2024) 144 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2024-202429

Published: 2024

Journal Articles

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Blood (2024) 144 (Supplement 1): 219.

https://doi.org/10.1182/blood-2024-200393

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2024) 144 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2024-208684

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2024-208890

Published: 2024

Journal Articles

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Emmanuel Almanza, Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero, Naveen Pemmaraju, Lucia Masarova, Sherry Pierce, Naval Daver, Alex Bataller, Guillermo Garcia-Manero, Amin M. Alousi, Nicholas J. Short, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2024-209558

Published: 2024

Journal Articles

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Anuya A. Natu, Clifford M. Csizmar, Terra L. Lasho, Rashmi Kanagal-Shamanna, Sanam Loghavi, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2024-209236

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

Journal Articles

Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds

Mahesh Swaminathan, Daniel Aaron Fox, Kelly S. Chien, Guillermo Montalban-Bravo, Danielle Hammond, Alexandre Bazinet, Sherry Pierce, Hyunsoo Hwang, Xuelin Huang, Koji Sasaki, Tapan M. Kadia, Koichi Takahashi, Courtney D. DiNardo, Elias Jabbour, Naval Daver, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 2438.

https://doi.org/10.1182/blood-2024-200390

Published: 2024

Journal Articles

Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL

Diane Habib, Hagop M. Kantarjian, Fadi G. Haddad, Nicholas J. Short, Nitin Jain, Jayastu Senapati, Kelly S. Chien, Guillermo Garcia-Manero, Zena Komrokji, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Koji Sasaki, Rebecca Garris, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2024-210501

Published: 2024

Journal Articles

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Hui Yang, Zhihong Fang, Yue Wei, Juan Jose Rodriguez Sevilla, Marcos Estecio, Guillermo Montalban-Bravo, Kelly S. Chien, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2024-207573

Published: 2024

Journal Articles

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood (2024) 144 (Supplement 1): 6126.

https://doi.org/10.1182/blood-2024-207413

Published: 2024

Journal Articles

Outcomes of Patients with IDH1 -Mutated Myeloid Neoplasms Treated with Olutasidenib

Kelly S. Chien, Koji Sasaki, Deborah McCue, Naval Daver, Tapan M. Kadia, Nicholas J. Short, Ghayas C. Issa, Guillermo Montalban-Bravo, Fadi G. Haddad, Danielle Hammond, Mahesh Swaminathan, Alexandre Bazinet, Farhad Ravandi, Guillermo Garcia-Manero, Sherry Pierce, Hagop M. Kantarjian, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 6042.

https://doi.org/10.1182/blood-2024-208611

Published: 2024

Journal Articles

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Blood (2024) 144 (Supplement 1): 1820.

https://doi.org/10.1182/blood-2024-209193

Published: 2024

Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1527.2.

https://doi.org/10.1182/blood-2024-208771

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds

Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL

CDC2-like Kinases (CLKs) Inhibition As a Novel Targeted Therapeutic Strategy in Myelodysplastic Syndromes (MDS)

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Outcomes of Patients with IDH1 -Mutated Myeloid Neoplasms Treated with Olutasidenib

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only